EXACT Sciences (EXAS) Given a $100.00 Price Target at UBS Group

Share on StockTwits

UBS Group set a $100.00 price objective on EXACT Sciences (NASDAQ:EXAS) in a research note published on Tuesday, www.tipranks.com reports. The firm currently has a buy rating on the medical research company’s stock.

Several other analysts have also issued reports on the company. Cowen increased their price objective on EXACT Sciences from $65.00 to $100.00 and gave the stock an outperform rating in a report on Wednesday, September 5th. Bank of America increased their price objective on EXACT Sciences from $68.00 to $92.00 and gave the stock a buy rating in a report on Thursday, September 6th. BidaskClub lowered EXACT Sciences from a buy rating to a hold rating in a report on Friday, September 14th. Robert W. Baird increased their price objective on EXACT Sciences from $74.00 to $85.00 and gave the stock an outperform rating in a report on Tuesday, September 11th. Finally, Canaccord Genuity increased their price objective on EXACT Sciences from $72.00 to $87.00 and gave the stock a buy rating in a report on Wednesday, September 12th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. EXACT Sciences currently has an average rating of Buy and an average target price of $84.08.

Shares of NASDAQ:EXAS opened at $75.30 on Tuesday. The company has a quick ratio of 15.37, a current ratio of 15.79 and a debt-to-equity ratio of 0.87. EXACT Sciences has a 1 year low of $37.36 and a 1 year high of $81.22. The firm has a market cap of $7.95 billion, a P/E ratio of -76.06 and a beta of 0.98.

EXACT Sciences (NASDAQ:EXAS) last announced its quarterly earnings data on Tuesday, October 30th. The medical research company reported ($0.37) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.42) by $0.05. EXACT Sciences had a negative return on equity of 20.10% and a negative net margin of 35.24%. The business had revenue of $118.29 million during the quarter, compared to analyst estimates of $109.33 million. During the same period last year, the company earned ($0.23) earnings per share. EXACT Sciences’s quarterly revenue was up 63.0% compared to the same quarter last year. Analysts anticipate that EXACT Sciences will post -1.44 earnings per share for the current year.

In other EXACT Sciences news, insider Graham Peter Lidgard sold 58,000 shares of the stock in a transaction on Monday, October 8th. The shares were sold at an average price of $69.36, for a total transaction of $4,022,880.00. Following the transaction, the insider now directly owns 204,684 shares of the company’s stock, valued at $14,196,882.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider D Scott Coward sold 2,190 shares of the stock in a transaction on Monday, October 1st. The stock was sold at an average price of $79.51, for a total transaction of $174,126.90. The disclosure for this sale can be found here. Insiders have sold 62,658 shares of company stock worth $4,381,737 over the last three months. Company insiders own 3.20% of the company’s stock.

Several large investors have recently modified their holdings of the company. Frontier Capital Management Co. LLC grew its position in shares of EXACT Sciences by 37.7% in the third quarter. Frontier Capital Management Co. LLC now owns 1,585,851 shares of the medical research company’s stock valued at $125,155,000 after purchasing an additional 434,184 shares during the last quarter. GWM Advisors LLC acquired a new stake in shares of EXACT Sciences in the third quarter valued at about $223,000. Columbus Circle Investors grew its position in shares of EXACT Sciences by 106.9% in the third quarter. Columbus Circle Investors now owns 317,443 shares of the medical research company’s stock valued at $25,053,000 after purchasing an additional 164,039 shares during the last quarter. Hodges Capital Management Inc. grew its position in shares of EXACT Sciences by 13.9% in the third quarter. Hodges Capital Management Inc. now owns 244,770 shares of the medical research company’s stock valued at $19,317,000 after purchasing an additional 29,930 shares during the last quarter. Finally, First Trust Advisors LP grew its position in shares of EXACT Sciences by 6,220.7% in the third quarter. First Trust Advisors LP now owns 524,744 shares of the medical research company’s stock valued at $41,413,000 after purchasing an additional 516,442 shares during the last quarter. 86.52% of the stock is currently owned by institutional investors.

About EXACT Sciences

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.

Further Reading: How analysts view the yield curve

Analyst Recommendations for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply